Back to results
US 11,690,874 B2Granted
Use of chimeric antigen receptor modified cells to treat autoimmune disease
AssigneesInnovative Cellular Therapeutics Holdings, Ltd., Zhejiang University
InventorsLei Xiao, Chengfei Pu, Zhao Wu, Linrong Lu
Life of this patent
Estimating the term…
Abstract
Embodiments of the present disclosure include a method for treating Systemic Lupus Erythematosus (SLE) using CD19 CAR T cells. The method includes administering to the human patient a pharmaceutically effective amount of a population of T cells of the human patient that express a chimeric antigen receptor (CAR) that comprises the amino acid sequence of, e.g., SEQ ID NO: 23.
Claims11
A method for treating Systemic Lupus Erythematosus (SLE) in a subject, the method comprising:
- administering to the subject a pharmaceutically effective amount of a population of T cells expressing a chimeric antigen receptor (CAR) that binds an antigen associated with B cells, wherein the CAR comprises amino acid sequence SEQ ID NO:
- 18.
Dependencies are inferred from the claim text.